Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
fMRI-behavioral Study of Cholinergic Augmentation With Donepezil in Healthy Sleep Deprived Adults
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Duke-NUS Graduate Medical School
- Target Recruit Count
- 43
- Registration Number
- NCT00800553
- Locations
- 🇸🇬
Cognitive Neuroscience Laboratory, Duke-NUS Graduate Medical School, Singapore, Singapore
Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Osaka University
- Target Recruit Count
- 24
- Registration Number
- NCT00776347
- Locations
- 🇯🇵
Osaka University Hospital, Suita,, Osaka, Japan
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- FORUM Pharmaceuticals Inc
- Target Recruit Count
- 49
- Registration Number
- NCT00766363
- Locations
- 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸Global Medical Institutes, LLC, Princeton, New Jersey, United States
🇺🇸Pacific Research Network, Inc., San Diego, California, United States
Pharmacokinetic Interaction Between AZD3480 and Donepezil
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT00713765
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 576
- Registration Number
- NCT00708552
- Locations
- 🇿🇦
GSK Investigational Site, Sunninghill, South Africa
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism
- Conditions
- Interventions
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 17
- Registration Number
- NCT00695136
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2009-07-30
- Lead Sponsor
- Epix Pharmaceuticals, Inc.
- Target Recruit Count
- 236
- Registration Number
- NCT00693004
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Meridien Research, St. Petersburg, Florida, United States
🇺🇸Torrance Clinical Research, Torrance, California, United States
Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT00688376
- Locations
- 🇺🇸
Road Runner Research Ltd., San Antonio, Texas, United States
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 22
- Registration Number
- NCT00619983
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Effect on Cognitive Performance and Safety/Tolerability of SSR180711C in Mild Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1
- Registration Number
- NCT00602680
- Locations
- 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.